Stay updated with breaking news from Trepl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group (NASDAQ:REPL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s […]
Replimune Group (NASDAQ:REPL – Get Rating) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $47.00 to $39.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 98.27% […]
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target […]
I've been working on Replit for roughly six years now, and as the team has grown, I've focused on the IDE (what we call…
Following our Series A announcement earlier this year, I'm thrilled to announce that we raised Series B financing from new and existing investors. This…